IP Library › Granted Patent US 11,401,279
Granted Patent B2
US 11,401,279 · App. 17/036,234 · Granted Aug 2, 2022

Pyrido[3,2-d]pyrimidine compounds as immunomodulators

Inventors: Jingwei Li (Westfield, NJ); Liangxing Wu (Wilmington, DE); Wenqing Yao (Chadds Ford, PA)
Assignee: Incyte Corporation
C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,401,279
App. No.
17/036,234
Granted
Aug 2, 2022
Kind
B2
Abstract

The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.

Claims (18)

1. A compound selected from:

(R)-4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;

(R)-4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; and

4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is (R)-4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein the compound is (R)-4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid.

4. The compound of claim 1 , wherein the compound is (R)-4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , wherein the compound is (R)-4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid.

6. The compound of claim 1 , wherein the compound is 4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 , wherein the compound is 4-(2-(2-((2-chloro-3′-((2-(difluoromethyl)-7-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid.

8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers.

9. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers.

10. A pharmaceutical composition comprising a compound of claim 3 , and one or more pharmaceutically acceptable excipients or carriers.

11. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers.

12. A pharmaceutical composition comprising a compound of claim 5 , and one or more pharmaceutically acceptable excipients or carriers.

13. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers.

14. A pharmaceutical composition comprising a compound of claim 7 , and one or more pharmaceutically acceptable excipients or carriers.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2020
From: LI, JINGWEI; WU, LIANGXING; YAO, WENQING
To: INCYTE CORPORATION
Reel/Frame 054402/0317 →
Continuity (2)
Provisional Application 62908317 · Sep 30, 2019
Related Publication 20210094976A1 · Apr 1, 2021
Cited By (6)
US 12,187,743 US 12,247,026 US 12,247,038 US 12,404,272 US 12,466,822 US 12,516,044